365 related articles for article (PubMed ID: 9431316)
1. Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.
Unger PD; Wang Q; Gordon RE; Stock R; Stone N
Arch Pathol Lab Med; 1997 Dec; 121(12):1265-8. PubMed ID: 9431316
[TBL] [Abstract][Full Text] [Related]
2. [Amyloidosis localized in the seminal vesicles: clinico-pathological review of 8 cases diagnosed in surgical specimens].
Caballero Martínez MC; Gómez Dorronsoro ML; Cuesta Alcalá JA; Amat Villegas I; Beloqui Pérez R; Martínez Peñuela JM; Monzón Muñoz FJ
Arch Esp Urol; 2003 May; 56(4):431-4. PubMed ID: 12830618
[TBL] [Abstract][Full Text] [Related]
3. Characterization of localized seminal vesicle amyloidosis causing hemospermia: an analysis using immunohistochemistry and magnetic resonance imaging.
Furuya S; Masumori N; Furuya R; Tsukamoto T; Isomura H; Tamakawa M
J Urol; 2005 Apr; 173(4):1273-7. PubMed ID: 15758775
[TBL] [Abstract][Full Text] [Related]
4. Localized amyloidosis of seminal vesicles: report of three cases in surgically obtained material.
Seidman JD; Shmookler BM; Connolly B; Lack EE
Mod Pathol; 1989 Nov; 2(6):671-5. PubMed ID: 2587572
[TBL] [Abstract][Full Text] [Related]
5. Amyloidosis of the seminal vesicle--a case report and review of the literature.
Maroun L; Jakobsen H; Kromann-Andersen B; Horn T
Scand J Urol Nephrol; 2003; 37(6):519-21. PubMed ID: 14675929
[TBL] [Abstract][Full Text] [Related]
6. The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis.
Quick CM; Gokden N; Sangoi AR; Brooks JD; McKenney JK
Hum Pathol; 2010 Aug; 41(8):1145-9. PubMed ID: 20413145
[TBL] [Abstract][Full Text] [Related]
7. [Amyloidosis of the seminal vesicles: a local condition with no systemic impact].
Harvey I; Têtu B
Ann Pathol; 2004 Jun; 24(3):236-40; quiz 227. PubMed ID: 15480258
[TBL] [Abstract][Full Text] [Related]
8. Seminal vesicle amyloidosis does not provide any protection from invasion by prostate cancer.
Erbersdobler A; Kollermann J; Graefen M; Röcken C; Schlomm T
BJU Int; 2009 Feb; 103(3):324-6. PubMed ID: 18778344
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.
Van der Kwast TH; Têtu B; Fradet Y; Dupont A; Gomez J; Cusan L; Diamond P; Labrie F
Prostate; 1996 Apr; 28(4):227-31. PubMed ID: 8602398
[TBL] [Abstract][Full Text] [Related]
10. Amyloidosis of seminal vesicles; incidence and pathologic characteristics.
Argon A; Sımşır A; Sarsik B; Tuna B; Yörükoğlu K; Nıflıoğlu GG; Sen S
Turk Patoloji Derg; 2012; 28(1):44-8. PubMed ID: 22207431
[TBL] [Abstract][Full Text] [Related]
11. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Raina R; Pahalajani G; Agarwal A; Zippe C
Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
[TBL] [Abstract][Full Text] [Related]
12. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
13. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
14. [Current value of seminal vesicle biopsy in patients with prostate cancer and influence of radical prostatectomy in patients with seminal vesicle invasion].
Losa CA; Fernando AB; Lázaro VA; Berlanga FF; Frago PS; López MA; Sanz MJ; Martínez PG; Sanz LA
Arch Esp Urol; 2006 Dec; 59(10):977-88. PubMed ID: 17283711
[TBL] [Abstract][Full Text] [Related]
15. Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy.
Tran TA; Jennings TA; Ross JS; Nazeer T
Am J Surg Pathol; 1998 Mar; 22(3):347-54. PubMed ID: 9500777
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
17. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
18. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
19. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?
Scolieri MJ; Altman A; Resnick MI
J Urol; 2000 Nov; 164(5):1465-72. PubMed ID: 11025684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
